News | Heart Failure | September 06, 2017

Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level

Survey finds that while clinicians identified most patients as high risk, few patients self-identified as high risk

Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level

September 6, 2017 — Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death, while few of those patients considered themselves to be at high risk, according to a study published recently in JACC: Heart Failure.

Physicians rated 161 patients for perceived risk for transplant, LVAD or death in the upcoming year. The patients were also surveyed about their perceptions of their life expectancy and willingness to undergo different treatment options.

Sixty-nine percent of the patients were considered at high risk for transplant, LVAD or death by their physicians. However, only 14 percent of patients considered themselves to be at high risk. Over 13 months of follow-up, 38 percent of patients experienced an endpoint: 21 percent deaths, 8 percent transplants and 9 percent LVAD implants.

“It was surprising that there were such drastic differences between patient perceptions and physician perceptions of heart failure disease severity,” said Amrut V. Ambardekar, M.D., an assistant professor in the division of cardiology at the University of Colorado and the study’s lead author. “We hope better understanding these differences will facilitate improved patient-physician communication regarding advanced heart failure therapies.”

Researchers also assessed patient willingness to consider other life sustaining therapies to treat advanced heart failure, such as ventilation, dialysis or a feeding tube. Among the patients identified as high-risk by physicians, 77 percent were willing to consider LVAD, but 63 percent indicated they would decline other simpler life-sustaining therapies.

“More than likely, these inconsistencies indicate a poor understanding of these treatment options,” Ambardekar said. “Patients may not fully appreciate the invasive nature of some of these procedures, so we probably need to look for better ways to educate our patients both on the severity of their disease and their treatment options – well before they need these advanced therapies.”

“This work highlights the importance of increasing the educational awareness of our patients and the need for more research in this area,” said Christopher M. O’Connor, M.D., FACC, editor-in-chief of JACC: Heart Failure.

Study limitations include that the categorization of physician and patient risk, as well as the patients’ opinions on treatment options, were made at the time of enrollment. According to the researchers, it is likely that perceptions of risk and the patients’ understanding of treatment options changed over the course of time.

For more information: www.heartfailure.onlinejacc.org

Related Content

The Role of Telomere Length in Cardiovascular Risk Assessment
Feature | Cardiac Diagnostics| October 19, 2017 | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratificatio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
SunTech Medical Receives Third-Party Validation of CT40 BP Spot-Check Device
News | Blood Pressure Monitor| October 11, 2017
October 11, 2017 — The CT40 spot-check device from SunTech Medical has received third-party validation for...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Majority of High-Risk Stroke Patients Not Being Screened for Common Risk Factors
News | Stroke| September 28, 2017
September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwid
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Overlay Init